Abstract:
Background: A double‑blind, randomized, placebo‑controlled Homoeopathic
Pathogenetic Trial (HPT) of Nanocurcumin was conducted using the accepted
guidelines, Ethical Committee approval, and scientific documentation. The
standardized potentization method was adopted to enhance the quality of the
pathogenetic trial. Various statistical calculations were used for evaluation of the
symptoms.
Aim: The aim of the study was to conduct an HPT of Nanocurcumin 6X, a nanosubstance
in dilution.
Materials and Methods: The drug Nanocurcumin 6X was proved through
double‑blind, placebo‑controlled method. The trial was done in 6X potency on 30
healthy provers who were screened by their pretrial medical examinations and routine
laboratory investigations. Of 30 provers, 7 were on placebo and 23 were on drug.
Medicine was prepared according to the principles of trituration given in Homoeopathic
Pharmacopeia of India. The signs and symptoms generated during the trial period
were noted by the provers and decoded and compiled afterwards.
Results: Of 23 provers who were on verum 17 provers manifested symptoms and out
of 7 provers who were on placebo 2 manifested symptoms.
Conclusion: The drug pathogenesis evolved indicates its therapeutic use in sinusitis,
migraine, dyspepsia, constipation, diarrhoea, dysmenorrhoea, pharyngitis, bronchitis, etc.
